Suivant

Lecture automatique

Emerging novel agents for the treatment of mastocytosis

1 Vues • 07/09/23
Partager
Intégrer
administrator
administrator
Les abonnés
0

Tracy George, MD, ARUP Laboratories, University of Utah, Salt Lake City, UT comments on the movement from broad, cladribine-based regimens to novel, targeted tyrosine kinase inhibitors (TKIs) such as avapritinib, for the treatment of systemic mastocytosis. Dr George also comments on the future development of antibody-based therapies, emphasizing the importance of more selective agents with fewer side effects. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Montre plus
0 commentaires sort Trier par
Commentaires de Facebook

Suivant

Lecture automatique